MediciNova develops small molecule therapeutics for serious diseases with unmet medical needs. Its focusing on MN-166 for neurological disorders like MS, ALS, and substance dependence, as well as other conditions. The company also has MN-221 for asthma exacerbations, MN-001 for fibrotic diseases, and MN-029 for solid tumor cancers.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 3.2 |